NEUROTROPHIC KERATITIS
Clinical trials for NEUROTROPHIC KERATITIS explained in plain language.
Never miss a new study
Get alerted when new NEUROTROPHIC KERATITIS trials appear
Sign up with your email to follow new studies for NEUROTROPHIC KERATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New eye drops show promise for rare corneal disease
Disease control CompletedThis study tested an eye drop called OXERVATE in 37 adults with stage 1 neurotrophic keratitis, a condition where the cornea loses feeling and doesn't heal properly. The treatment was given for 8 weeks, and patients were followed for 24 weeks to see if the cornea healed. The goal…
Matched conditions: NEUROTROPHIC KERATITIS
Phase: PHASE4 • Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated May 26, 2026 09:21 UTC
-
OXERVATE eye drops show lasting healing for rare eye disease
Disease control CompletedThis study looked at the long-term safety and effectiveness of OXERVATE eye drops in 24 people with stage 1 neurotrophic keratitis, a rare eye condition that can damage the cornea. Participants had already completed the DEFENDO study. Researchers checked if the cornea stayed heal…
Matched conditions: NEUROTROPHIC KERATITIS
Sponsor: Dompé Farmaceutici S.p.A • Aim: Disease control
Last updated May 26, 2026 09:02 UTC
-
New eye drops show promise for rare corneal disease
Disease control CompletedThis study tested an experimental eye drop called CSB-001 in 131 people with a rare eye disease called neurotrophic keratitis, which causes damage to the cornea (the clear front part of the eye). Participants used the drops four times a day for 8 weeks. The goal was to see if the…
Matched conditions: NEUROTROPHIC KERATITIS
Phase: PHASE1, PHASE2 • Sponsor: Claris Biotherapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
New eye drops tested for rare corneal disease
Symptom relief CompletedThis early-stage trial tested the safety of an experimental eye drop called STSP-0902 in 82 healthy adults aged 18 to 45. The study checked for side effects and how the drug moves through the body after single and multiple doses. It is a first step toward developing a treatment f…
Matched conditions: NEUROTROPHIC KERATITIS
Phase: PHASE1 • Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd • Aim: Symptom relief
Last updated May 26, 2026 09:22 UTC